Correlation Between Unicycive Therapeutics and Cadrenal Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Cadrenal Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Cadrenal Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Unicycive Therapeutics and Cadrenal Therapeutics, Common, you can compare the effects of market volatilities on Unicycive Therapeutics and Cadrenal Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Cadrenal Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Cadrenal Therapeutics,.

Diversification Opportunities for Unicycive Therapeutics and Cadrenal Therapeutics,

0.64
  Correlation Coefficient

Poor diversification

The 3 months correlation between Unicycive and Cadrenal is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Cadrenal Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cadrenal Therapeutics, and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Cadrenal Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cadrenal Therapeutics, has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Cadrenal Therapeutics, go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and Cadrenal Therapeutics,

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 0.67 times more return on investment than Cadrenal Therapeutics,. However, Unicycive Therapeutics is 1.5 times less risky than Cadrenal Therapeutics,. It trades about 0.24 of its potential returns per unit of risk. Cadrenal Therapeutics, Common is currently generating about 0.16 per unit of risk. If you would invest  32.00  in Unicycive Therapeutics on September 3, 2024 and sell it today you would earn a total of  37.00  from holding Unicycive Therapeutics or generate 115.63% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Unicycive Therapeutics  vs.  Cadrenal Therapeutics, Common

 Performance 
       Timeline  
Unicycive Therapeutics 

Risk-Adjusted Performance

19 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Cadrenal Therapeutics, 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Unicycive Therapeutics and Cadrenal Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Unicycive Therapeutics and Cadrenal Therapeutics,

The main advantage of trading using opposite Unicycive Therapeutics and Cadrenal Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Cadrenal Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cadrenal Therapeutics, will offset losses from the drop in Cadrenal Therapeutics,'s long position.
The idea behind Unicycive Therapeutics and Cadrenal Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios